Navigation Links
Andrew J. Dannenberg, M.D., honored with AACR-Prevent Cancer Foundation Award
Date:10/19/2011

PHILADELPHIA The AACR will present the 2011 AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research to Andrew J. Dannenberg, M.D., at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011. Dannenberg is director of the Weill Cornell Cancer Center and director of cancer prevention at New York-Presbyterian/Weill Cornell Medical Center. He is also the Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medical College.

Dannenberg's work has provided the basis for the transformative discovery linking obesity, inflammation and breast cancer. He is recognized for his work on the inflammation-cancer connection with an emphasis on prostaglandin biology. Dannenberg's research has been of major importance in explaining why levels of procarcinogenic prostaglandins are increased in inflamed tissues and tumors. He has also made major contributions to our understanding of why nonsteroidal anti-inflammatory drugs show chemopreventive activity.

The AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research is given annually for seminal laboratory, translational, clinical, epidemiological or behavioral science contributions to the field of cancer prevention.

Dannenberg's significant contributions include demonstrating that COX-2 was overexpressed in a variety of premalignant lesions and cancers; elucidating the mechanisms by which oncogenes, tumor suppressor genes, carcinogens and tumor promoters regulate COX-2 gene expression; utilizing both pharmacological and genetic strategies to establish the importance of targeting prostaglandin synthesis as a bona fide prevention strategy; defining the signal transduction pathways by which dietary and synthetic chemopreventive agents suppress COX-2 transcription and prostaglandin synthesis; and determining the signaling mechanism by which COX-derived prostaglandin E2 induced aromatase, the rate-limiting enzyme responsible for estrogen synthesis. This latter work led to an observational study in which the use of aspirin was associated with a reduced risk for hormone receptor-positive breast cancer.

In his most recent work that provides new insights into the link between obesity, inflammation and breast cancer, Dannenberg conducted a preclinical study in which he used experimental models to demonstrate the presence of the obesityinflammationaromatase axis in the mammary gland. As a result, COX-2-derived PGE2 appeared to play an important role in inducing aromatase in the mammary glands of obese mice. Subsequently, he successfully translated these preclinical findings.

Dannenberg will present his lecture, "Obesity and Breast Inflammation: Implications for Cancer Prevention," on Sunday, Oct. 23, 2011, at 5:15 p.m.


'/>"/>

Contact: Michele Sharp
Michele.Sharp@aacr.org
267-446-7156
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Cedars-Sinai Medical Center Names Beverly Hills Plastic Surgeon Dr. Andrew Cohen as Chief of the Center for Plastic and Reconstructive Surgery
2. Counseling Suicidal Clients by Andrew Reeves
3. UCSF neurologist William Seeley, M.D., named MacArthur Fellow
4. Dale Browne, M.D., ear, nose, and throat specialist, receives award from National Medical Society
5. Ching-Hon Pui, M.D., honored by the American Society of Hematology for work in childhood cancer
6. BUS Jeffrey H. Samet, M.D., selected as a 2011 NIDA International Program Awards of Excellence winner
7. Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
8. BIDMCs Peter Weller, M.D., receives NIH MERIT Award
9. BIDMC neurologist Bernard Chang, M.D., receives award for epilepsy research
10. Alfred B. Knight, M.D., Scott & White Healthcare, presents at 8th Annual World Health Care Congress
11. Ching-Hon Pui, M.D., recognized with American Association for Cancer Research award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology: